MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and ...
The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
MSD has spent €500M acquiring a Dundalk vaccine plant and several other facilities around Ireland in an early year boost for ...
China's WuXi Biologics has confirmed it will sell its vaccine facility in Ireland to US drugmaker Merck & Co for about €500 ...
ATC employs more than 280 people, with plans to have increased headcount to 300 by 2026 and to have added two further ...
The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s ...
News that pharmaceutical company MSD Ireland has acquired the WuXi Vaccines manufacturing facility in Dundalk has been ...
In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...
MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi ...
US multinational pharmaceutical company MSD has today (6 January) announced the acquisition of WuXi Vaccines’ Dundalk site.
The Dundalk site was WuXi's first manufacturing investment in Europe and the company’s first investment of this scale outside ...
The pharmaceutical firm MSD is buying out the WuXi Vaccines manufacturing plant in Dundalk, in a €500m deal. The American company says that in addition to the 150 jobs at the Dundalk facility, it is ...